|
1
|
Rock GA, Shumak KH, Buskard NA, Blanchette
VS, Kelton JG, Nair RC and Spasoff RA: Comparison of plasma
exchange with plasma infusion in the treatment of thrombotic
thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J
Med. 325:393–397. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsai HM: Current concepts in thrombotic
thrombocytopenic purpura. Annu Rev Med. 57:419–436. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Allford SL, Hunt BJ, Rose P and Machin SJ:
Haemostasis and Thrombosis Task Force, British Committee for
Standards in Haemotology: Guidelines on the diagnosis and
management of the thrombotic microangiopathic haemolytic anaemias.
Br J Haematol. 120:556–573. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zaja F, Baccarani M, Mazza P, Bocchia M,
Gugliotta L, Zaccaria A, Vianelli N, Defina M, Tieghi A, Amadori S,
et al: Dexamethasone plus rituximab yields higher sustained
response rates than dexamethasone monotherapy in adults with
primary immune thrombocytopenia. Blood. 115:2755–2762. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Patel VL, Mahévas M, Lee SY, Stasi R,
Cunningham-Rundles S, Godeau B, Kanter J, Neufeld E, Taube T,
Ramenghi U, et al: Outcomes 5 years after response to rituximab
therapy in children and adults with immune thrombocytopenia. Blood.
119:5989–5995. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zaja F, Vianelli N, Volpetti S, Battista
ML, Defina M, Palmieri S, Bocchia M, Medeot M, De Luca S, Ferrara
F, et al: Low-dose rituximab in adult patients with primary immune
thrombocytopenia. Eur J Haematol. 85:329–334. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zecca M, De Stephano P, Nobili B and
Locatelli F: Anti-CD20 monoclonal antibody for the treatment of
severe, immune-mediated, pure red cell aplasia and hemolytic
anaemia. Blood. 97:3995–39972001. View Article : Google Scholar
|
|
8
|
Fakhouri F, Vernant JP, Veyradier A, Wolf
M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P,
Deroure B, et al: Efficiency of curative and prophylactic treatment
with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic
purpura: A study of 11 cases. Blood. 106:1932–1937. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Scully M, McDonald V, Cavenagh J, Hunt BJ,
Longair I, Cohen H and Machin SJ: A phase 2 study of the safety and
efficacy of rituximab with plasma exchange in acute acquired
thrombotic thrombocytopenic purpura. Blood. 118:1746–1753. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Froissart A, Buffet M, Veyradier A,
Poullin P, Provôt F, Malot S, Schwarzinger M, Galicier L, Vanhille
P, Vernant JP, et al: Efficacy and safety of first-line rituximab
in severe, acquired thrombotic thrombocytopenic purpura with a
suboptimal response to plasma exchange. Experience of the French
thrombotic microangiopathies reference center. Crit Care Med.
40:104–111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iioka F, Shimomura D, Ishii T, Maesako Y,
Ohgoe K, Nakamura F, Matsuo S and Ohno H: Short- and long-term
effects of rituximab for the treatment of thrombotic
thrombocytopenic purpura: Four case reports. Int J Hematol.
96:506–512. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
de la Rubia JD, Moscardó F, Gómez MJ,
Guardia R, Rodríguez P, Sebrango A, Zamora C, Debén G, Goterris R,
López R, et al: Efficacy and safety of rituximab in adult patients
with idiopathic relapsing or refractory thrombotic thrombocytopenic
purpura: Results of a Spanish multicenter study. Transfus Apher
Sci. 43:299–303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Scully M, Hunt BJ, Benjamin S, Liesner R,
Rose P, Peyvandi F, Cheung B and Machin SJ: British Committee for
Standards in Haematology: Guidelines on the diagnosis and
management of thrombotic thrombocytopenic purpura and other
thrombotic microangiopathies. Br J Haematol. 158:323–335. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pequeño-Luévano M, Villarreal-Martínez L,
Jaime-Pérez JC, Gómez-de-León A, Cantú-Rodríguez OG, González-Llano
O and Gómez-Almaguer D: Low-dose rituximab for the treatment of
acute thrombotic thrombocytopenic purpura: Report of four cases.
Hematology. 18:233–236. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Taube T, Schmid H, Reinhard H, von
Stackelberg A and Overberg US: Effect of a single dose of rituximab
in chronic immune thrombocytopenic purpura in childhood.
Haematologica. 90:281–283. 2005.PubMed/NCBI
|
|
16
|
Zaja F, Battista ML, Pirrotta MT, Palmieri
S, Montagna M, Vianelli N, Marin L, Cavallin M, Bocchia M, Defina
M, et al: Lower dose rituximab is active in adults patients with
idiopathic thrombocytopenic purpura. Haematologica. 93:930–933.
2008. View Article : Google Scholar : PubMed/NCBI
|
